全文获取类型
收费全文 | 377761篇 |
免费 | 25017篇 |
国内免费 | 2793篇 |
学科分类
医药卫生 | 405571篇 |
出版年
2021年 | 2432篇 |
2019年 | 2743篇 |
2018年 | 4539篇 |
2017年 | 3446篇 |
2016年 | 3555篇 |
2015年 | 4043篇 |
2014年 | 5737篇 |
2013年 | 7408篇 |
2012年 | 10078篇 |
2011年 | 10255篇 |
2010年 | 6210篇 |
2009年 | 5861篇 |
2008年 | 9490篇 |
2007年 | 10331篇 |
2006年 | 10253篇 |
2005年 | 9306篇 |
2004年 | 8813篇 |
2003年 | 8562篇 |
2002年 | 8210篇 |
2001年 | 28275篇 |
2000年 | 28772篇 |
1999年 | 23627篇 |
1998年 | 5040篇 |
1997年 | 4113篇 |
1996年 | 3688篇 |
1995年 | 3475篇 |
1994年 | 3107篇 |
1993年 | 2843篇 |
1992年 | 16050篇 |
1991年 | 14828篇 |
1990年 | 14172篇 |
1989年 | 13969篇 |
1988年 | 12593篇 |
1987年 | 12071篇 |
1986年 | 11111篇 |
1985年 | 10323篇 |
1984年 | 6915篇 |
1983年 | 5606篇 |
1982年 | 2726篇 |
1979年 | 5486篇 |
1978年 | 3347篇 |
1977年 | 2964篇 |
1975年 | 2641篇 |
1974年 | 3071篇 |
1973年 | 2868篇 |
1972年 | 2835篇 |
1971年 | 2778篇 |
1970年 | 2514篇 |
1969年 | 2547篇 |
1968年 | 2255篇 |
排序方式: 共有10000条查询结果,搜索用时 435 毫秒
71.
Elena V. Preobrazhenskaya Aglaya G. Iyevleva Amina M. Suleymanova Vladislav I. Tiurin Natalia V. Mitiushkina Ilya V. Bizin Alexandr O. Ivanstov Olga A. Gorustovich Kseniya V. Shelekhova Denis Y. Kachanov Svetlana R. Varfolomeeva Vitaliy Y. Roschin Anna N. Kazakova Dmitriy V. Litvinov Tatiana V. Shamanskaya Nikita A. Savelov Evgeny N. Suspitsin Evgeny N. Imyanitov 《Pediatric blood & cancer》2020,67(5)
72.
73.
目的:以灰毡毛忍冬为材料,克隆对-香豆酸3-羟化酶(LmC3H1)基因,进行生物信息学和表达模式分析,结合绿原酸含量,研究推测灰毡毛忍冬LmC3H1基因的功能。方法:通过逆转录聚合酶链式反应(RT-PCR)和RACE技术克隆LmC3H1基因的全长c DNA序列,对该序列进行生物信息学分析,并利用实时荧光定量PCR(Real-time PCR)和HPLC分别测定灰毡毛忍冬茎、叶及不同花期花中LmC3H1的相对表达量及绿原酸含量。结果:克隆得LmC3H1(Gen Bank:MN177695)基因,开放阅读框(ORF)长度为1 533 bp,编码510个氨基酸,推测其分子式为C_(2618)H_(4134)N_(718)O_(727)S_(22),相对分子质量为58 005.32,等电点8.92,为亲水性蛋白,定位于叶绿体中,具有跨膜区域LLLIPAVLFLISLVYPLI,含有细胞色素P450的保守结构域CYTOCHROME_P450(422-433 aa);Real-time PCR结果显示,LmC3H1在灰毡毛忍冬茎、叶及不同花期花有不同程度的表达,其中在花发育阶段,白色花蕾期相对表达量最高,花蕾初期及白色开花期次之;白色花蕾期花与茎、叶比,花的相对表达量最高,叶的最低;HPLC结果显示,从绿白色花蕾期到金黄色开花期绿原酸含量呈上升趋势,金黄色开花期含量最高,不同器官中,花中绿原酸最高,茎最低。结论:克隆得到灰毡毛忍冬LmC3H1基因,推测LmC3H1可能参与灰毡毛忍冬花绿原酸的生物合成。该研究为进一步研究该基因的功能及探究灰毡毛忍冬绿原酸生物合成和调节机制提供了依据,同时为遗传改良灰毡毛忍冬品质奠定了基础。 相似文献
74.
75.
76.
77.
78.
79.
Harsh Goel Joshua Melot Matthew D. Krinock Ashish Kumar Sunil K. Nadar Gregory Y. H. Lip 《Annals of medicine》2020,52(8):444-461
Abstract Cardiac troponins (cTn) are currently the standard of care for the diagnosis of acute coronary syndromes (ACS) in patients presenting to the emergency department (ED) with chest pain (CP). However, their plasma kinetics necessitate a prolonged ED stay or overnight hospital admission, especially in those presenting early after CP onset. Moreover, ruling out ACS in low-risk patients requires prolonged ED observation or overnight hospital admission to allow serial measurements of c-Tn, adding cost. Heart-type fatty acid-binding protein (H-FABP) is a novel marker of myocardial injury with putative advantages over cTn. Being present in abundance in the myocellular cytoplasm, it is released rapidly (<1?h) after the onset of myocardial injury and could potentially play an important role in both earlier diagnosis of high-risk patients presenting early after CP onset, as well as in risk-stratifying low-risk patients rapidly. Like cTn, H-FABP also has a potential role as a prognostic marker in other conditions where the myocardial injury occurs, such as acute congestive heart failure (CHF) and acute pulmonary embolism (PE). This review provides an overview of the evidence examining the role of H-FABP in early diagnosis and risk stratification of patients with CP and in non-ACS conditions associated with myocardial injury.
- Key messages
-
Heart-type fatty acid-binding protein is a biomarker that is elevated early in myocardial injury
-
The routine use in the emergency department complements the use of troponins in ruling out acute coronary syndromes in patients presenting early with chest pain
-
It also is useful in risk stratifying patients with other conditions such as heart failure and acute pulmonary embolism.
80.
Yu Akazawa Yuki Saito Toshiaki Yoshikawa Keigo Saito Kazuto Nosaka Manami Shimomura Shoichi Mizuno Yasunari Nakamoto Tetsuya Nakatsura 《Cancer science》2020,111(8):2736-2746
Lung cancer is the leading cause of cancer‐related deaths worldwide. Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) often have good clinical activity against non–small cell lung cancer (NSCLC) with activating EGFR mutations. Osimertinib, which is a third‐generation EGFR‐TKI, has a clinical effect even on NSCLC harboring the threonine to methionine change at codon 790 of EGFR (EGFR T790M) mutation that causes TKI resistance. However, most NSCLC patients develop acquired resistance to osimertinib within approximately 1 year, and 40% of these patients have the EGFR T790M and cysteine to serine change at codon 797 (C797S) mutations. Therefore, there is an urgent need for the development of novel treatment strategies for NSCLC patients with the EGFR T790M/C797S mutation. In this study, we identified the EGFR T790M/C797S mutation‐derived peptide (790‐799) (MQLMPFGSLL) that binds the human leukocyte antigen (HLA)‐A*02:01, and successfully established EGFR T790M/C797S‐peptide‐specific CTL clones from human PBMC of HLA‐A2 healthy donors. One established CTL clone demonstrated adequate cytotoxicity against T2 cells pulsed with the EGFR T790M/C797S peptide. This CTL clone also had high reactivity against cancer cells that expressed an endogenous EGFR T790M/C797S peptide using an interferon‐γ (IFN‐γ) enzyme‐linked immunospot (ELISPOT) assay. In addition, we demonstrated using a mouse model that EGFR T790M/C797S peptide‐specific CTL were induced by EGFR T790M/C797S peptide vaccine in vivo. These findings suggest that an immunotherapy targeting a neoantigen derived from EGFR T790M/C797S mutation could be a useful novel therapeutic strategy for NSCLC patients with EGFR‐TKI resistance, especially those resistant to osimertinib. 相似文献